K Rossing

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Progression of nephropathy in type 2 diabetic patients
    Kasper Rossing
    Department of Physiology, Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1596-605. 2004
  2. ncbi request reprint Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:2268-74. 2003
  3. ncbi request reprint Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:193-205. 2005
  4. ncbi request reprint Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1190-8. 2005
  5. ncbi request reprint Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Care 26:569-74. 2003
  6. ncbi request reprint Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
    K Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetologia 48:2241-7. 2005
  7. pmc Urinary proteomics in diabetes and CKD
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    J Am Soc Nephrol 19:1283-90. 2008
  8. ncbi request reprint Pregnancy and progression of diabetic nephropathy
    K Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Diabetologia 45:36-41. 2002
  9. ncbi request reprint Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 25:95-100. 2002
  10. doi request reprint Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial
    K J Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Diabetologia 52:46-9. 2009

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Progression of nephropathy in type 2 diabetic patients
    Kasper Rossing
    Department of Physiology, Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1596-605. 2004
    ....
  2. ncbi request reprint Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:2268-74. 2003
    ....
  3. ncbi request reprint Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:193-205. 2005
    ..New insights into the pathogenesis and treatment of diabetic renal disease may emerge from recent advances in proteomics using high-throughput mass spectrometry (MS) of urine...
  4. ncbi request reprint Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1190-8. 2005
    ..The purpose of this study was to evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultrahigh doses of irbesartan in type 2 diabetic patients with microalbuminuria...
  5. ncbi request reprint Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Care 26:569-74. 2003
    ..In the present study, we evaluated 24-h blood pressure patterns in a subpopulation of the IRMA2 trial...
  6. ncbi request reprint Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
    K Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetologia 48:2241-7. 2005
    ..We evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy...
  7. pmc Urinary proteomics in diabetes and CKD
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    J Am Soc Nephrol 19:1283-90. 2008
    ..In conclusion, this study shows that analysis of the urinary proteome may allow early detection of diabetic nephropathy and may provide prognostic information...
  8. ncbi request reprint Pregnancy and progression of diabetic nephropathy
    K Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Diabetologia 45:36-41. 2002
    ..Pregnancy could damage kidney function in diabetic nephropathy. We investigated the long-term impact of pregnancy on the progression of diabetic nephropathy...
  9. ncbi request reprint Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 25:95-100. 2002
    ..g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS)...
  10. doi request reprint Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial
    K J Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Diabetologia 52:46-9. 2009
    ....
  11. ncbi request reprint Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
    K J Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 70:536-42. 2006
    ....
  12. ncbi request reprint Evolving strategies for renoprotection: diabetic nephropathy
    H H Parving
    Steno Diabetes Center, Copenhagen, Denmark
    Curr Opin Nephrol Hypertens 10:515-22. 2001
    ..Many potential treatment modalities in preventing and treating diabetic nephropathy are presently being evaluated...
  13. ncbi request reprint Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone
    K J Schjoedt
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Horm Metab Res 37:4-8. 2005
    ..The beneficial response may be influenced by genetic factors and reductions in blood pressure and plasma aldosterone concentrations...
  14. ncbi request reprint Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Diabetes Care 28:2106-12. 2005
    ....
  15. ncbi request reprint Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark Faculty of Health Science, University of Aarhus, Aarhus, Denmark
    Diabetes Care 26:150-5. 2003
    ..We evaluated the optimal dose of the angiotensin II receptor antagonist candesartan cilexetil for renoprotection as reflected by short-term changes in albuminuria in hypertensive type 2 diabetic patients with nephropathy...
  16. ncbi request reprint Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients
    P Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    J Intern Med 254:464-71. 2003
    ..We tested the impact of short-term hyperglycaemia on systemic blood pressure and regulatory hormones in type 1 diabetic patients...
  17. ncbi request reprint Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
    Hans Henrik Parving
    Steno Diabetes Center, Copenhagen, Denmark
    Semin Nephrol 24:147-57. 2004
    ..The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy...
  18. ncbi request reprint Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Nephrol Dial Transplant 17:1019-24. 2002
    ..We tested the effect of dual blockade of the renin-angiotensin system (RAS) in these patients...
  19. ncbi request reprint Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Curr Opin Nephrol Hypertens 13:319-24. 2004
    ....
  20. ncbi request reprint Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 29:1024-30. 2006
    ....
  21. ncbi request reprint Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:2829-36. 2005
    ..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
  22. ncbi request reprint Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:1258-64. 2003
    ..To assess recent trends in the cumulative incidence of diabetic microangiopathy in type 1 diabetes, we analyzed data from long-term prospective observational studies lasting >/=20 years...
  23. ncbi request reprint Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 63:1874-80. 2003
    ....
  24. ncbi request reprint Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 67:2325-9. 2005
    ..The present study aimed to investigate the short- and long term effects of angiotensin II receptor blockade by Losartan on urinary CTGF levels in hypertensive type 1 diabetic patients with diabetic nephropathy...
  25. ncbi request reprint Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring
    Kasper Rossing
    Steno Diabetes Centre, Gentofte
    Dan Med Bull 54:79-98. 2007